The RUNX Transcriptional Coregulator, CBFβ, Suppresses Migration of ER+ Breast Cancer Cells by Repressing ERα-Mediated Expression of the Migratory Factor TFF1
- 1 May 2019
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 17 (5) , 1015-1023
Abstract
Core binding factor β (CBFβ), the essential coregulator of RUNX transcription factors, is one of the most frequently mutated genes in estrogen receptor–positive (ER+) breast cancer. Many of these mutations are nonsense mutations and are predicted to result in loss of function, suggesting a tumor suppressor role for CBFβ. However, the impact of missense mutations and the loss of CBFβ in ER+ breast cancer cells have not been determined. Here we demonstrate that missense mutations in CBFβ accumulate near the Runt domain–binding region. These mutations inhibit the ability of CBFβ to form CBFβ–Runx–DNA complexes. We further show that deletion of CBFβ, using CRISPR-Cas9, in ER+ MCF7 cells results in an increase in cell migration. This increase in migration is dependent on the presence of ERα. Analysis of the potential mechanism revealed that the increase in migration is driven by the coregulation of Trefoil factor 1 (TFF1) by CBFβ and ERα. RUNX1–CBFβ acts to repress ERα-activated expression of TFF1. TFF1 is a motogen that stimulates migration and we show that knockdown of TFF1 in CBFβ−/− cells inhibits the migratory phenotype. Our findings reveal a new mechanism by which RUNX1–CBFβ and ERα combine to regulate gene expression and a new role for RUNX1–CBFβ in the prevention of cell migration by suppressing the expression of the motogen TFF1. Implications: Mutations in CBFβ contribute to the development of breast cancer by inducing a metastatic phenotype that is dependent on ER.Keywords
Funding Information
- Cancer Research UKCancer Research UK (CRUK)
- Breast Cancer Now (2013MayPR01)
This publication has 32 references indexed in Scilit:
- Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1–CBFβ interactionProceedings of the National Academy of Sciences, 2012
- Whole-genome analysis informs breast cancer response to aromatase inhibitionNature, 2012
- Deficiency in trefoil factor 1 (TFF1) increases tumorigenicity of human breast cancer cells and mammary tumor development in TFF1-knockout miceOncogene, 2011
- Integrative genomics viewerNature Biotechnology, 2011
- The Runx transcriptional co-activator, CBFβ, is essential for invasion of breast cancer cellsMolecular Cancer, 2010
- ChIP‐Seq of ERα and RNA polymerase II defines genes differentially responding to ligandsThe EMBO Journal, 2009
- Mechanisms of primary and secondary estrogen target gene regulation in breast cancer cellsNucleic Acids Research, 2007
- Genome-wide analysis of estrogen receptor binding sitesNature Genetics, 2006
- Erratum: Trefoil factors: initiators of mucosal healingNature Reviews Molecular Cell Biology, 2003
- Cbfβ interacts with Runx2 and has a critical role in bone developmentNature Genetics, 2002